Symbols

MYGN

Myriad Genetics·NASDAQ

--(--)

MYGN fundamentals

MYGN Q4 2025 Earnings

Myriad Genetics (MYGN) released its earnings on Feb 23, 2026: revenue was 209.80M (YoY -0.38%), beat estimates; EPS was 0.04 (YoY +33.33%), beat estimates.

Revenue / YoY

209.80M

-0.38%

EPS / YoY

0.04

+33.33%

Report date

Feb 23, 2026

MYGN Earnings Call Summary for Q4,2025

Q4 2025 Strong Execution: Revenue $209.8M, 9% test volume growth in hereditary cancer, and 9% GeneSight volume growth despite UHC headwinds.
2026 Growth Catalysts: $35M+ investment in commercial teams, 3 major product launches (MRD, AI-Prolaris, FirstGene), and prenatal recovery.
MRD Alpha Launch: Q1 2026 with select centers; tracking repeat orders, operational efficiency, and user experience.
Financial Discipline: 2026 EBITDA guidance $37-49M, balanced growth investment with profitability focus.
Long-Term Vision: High single-digit to low double-digit growth in 2027+ via MRD, AI, and expanded prenatal portfolio.

Earnings

EPS

Revenue

Revenue & Expenses

MYGN has released its 2025 Q4 earnings report, with revenue of 209.80M, reflecting a YoY change of -0.38%, and net profit of -7.90M, showing a YoY change of 81.41%. The Sankey diagram below clearly presents MYGN's revenue sources and cost distribution.

Key Indicators

Myriad Genetics (MYGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Myriad Genetics (MYGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Myriad Genetics (MYGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Myriad Genetics (MYGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown